Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis

Plasma levels of chemokines decrease during elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis

Background: Cystic fibrosis (CF) is associated with dysregulated immune responses, exaggerated inflammation and chronic infection. CF transmembrane conductance regulator (CFTR) modulator therapies directly target the underlying protein defects and resulted in significant clinical benefits for people...

Full description

Bibliographic Details
Main Authors: Dirk Westhölter, Johannes Pipping, Jonas Raspe, Mona Schmitz, Sivagurunathan Sutharsan, Svenja Straßburg, Matthias Welsner, Christian Taube, Sebastian Reuter
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Heliyon
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023106360

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023106360

Similar Items